Quotient Bioresearch Extends Transfer Agreement with GE Healthcare

An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed. This extension will assure customers of a smooth transition and uninterrupted supply of carbon-14 labelled compounds during the move of Amersham

Radiolabelling Services from the existing site to its new facility in Cardiff this Spring.

At the time of the acquisition in June 2009, Quotient formed its Chemistry & Metabolism business unit and announced a £15 million investment in a new facility in Cardiff; the timescale for completion and the transfer of

production has been confirmed for Spring 2010.

Stephen Lewinton, Managing Director, Quotient Chemistry & Metabolism, said: “We are very pleased with the progress of our new building. The extension we have agreed with GE Healthcare allows client work to continue as normal at the existing labs until commissioning of the new facility is completed. This gives us additional capability by allowing transfer of synthesis intermediates with no project delays and provides greater flexibility on completing regulatory processes and validations at the new facility. The bottom line is that we can assure our clients that at no time will all of the labs be closed, and so service can effectively be maintained throughout the transition period.”